Novavax (NVAX) Starts Developing Omicron-Specific COVID Jab Posted byZacks Equity Research December 3, 2021 Leave a comment on Novavax (NVAX) Starts Developing Omicron-Specific COVID Jab Novavax (NVAX) begins evaluating its COVID-19 vaccine against the Omicron variant. The company also starts developing an Omicron-specific COVID-19 vaccine.